Endometrial cancer: redefining the molecular-targeted approach Jesse Lopes da SilvaEduardo PaulinoAndréia Cristina de Melo Review Article 03 May 2015 Pages: 1 - 11
A proof of concept trial of the anti-EGFR antibody mixture Sym004 in patients with squamous cell carcinoma of the head and neck J.-P. MachielsP. SpecenierT. C. Gauler Original Article 08 May 2015 Pages: 13 - 20
Sandwich-like neoadjuvant therapy with bevacizumab for locally advanced rectal cancer: a phase II trial Jian XiaoZexian ChenJianping Wang Original Article 08 May 2015 Pages: 21 - 27
Pilot study of modified FOLFOX6 adjuvant chemotherapy for high-risk rectal cancer treated with neoadjuvant chemoradiotherapy Soo Jung LeeByung Woog KangJong Gwang Kim Original Article 09 May 2015 Pages: 29 - 34
Direct and indirect targeting of MYC to treat acute myeloid leukemia Sam BrondfieldSushma UmeshScott C. Kogan Original Article Open access 09 May 2015 Pages: 35 - 46
Influence of metastatic disease on the usefulness of uracil pharmacokinetics as a screening tool for DPD activity in colorectal cancer patients Maurice C. van StaverenFrans OpdamHans Gelderblom Original Article 10 May 2015 Pages: 47 - 52
Extension of the Calvert formula to patients with severe renal insufficiency Tomoyo OguriTomoya ShimokataYuichi Ando Original Article 10 May 2015 Pages: 53 - 59
Phase II trial of everolimus in patients with refractory metastatic adenocarcinoma of the esophagus, gastroesophageal junction and stomach: possible role for predictive biomarkers Zev A. WainbergHeloisa P. SoaresJ. Randolph Hecht Original Article 13 May 2015 Pages: 61 - 67
Second-line docetaxel for patients with platinum-refractory advanced non-small cell lung cancer and interstitial pneumonia Naohiro WatanabeSeiji NihoKoichi Goto Original Article 15 May 2015 Pages: 69 - 74
Initial safety report on the tolerability of modified FOLFOX6 as adjuvant therapy in patients with curatively resected stage II or III colon cancer (JFMC41-1001-C2: JOIN trial) Masahito KotakaTakayuki YoshinoToshiaki Watanabe Original Article Open access 16 May 2015 Pages: 75 - 84
Association of fludarabine pharmacokinetic/dynamic biomarkers with donor chimerism in nonmyeloablative HCT recipients Jeannine S. McCuneDonald E. MagerShelly Heimfeld Original Article 17 May 2015 Pages: 85 - 96
Double-blind, placebo-controlled, randomized phase II study of TJ-14 (Hangeshashinto) for infusional fluorinated-pyrimidine-based colorectal cancer chemotherapy-induced oral mucositis Chu MatsudaYoshinori MunemotoToru Kono Original Article Open access 17 May 2015 Pages: 97 - 103
Interactions of cyclin-dependent kinase inhibitors AT-7519, flavopiridol and SNS-032 with ABCB1, ABCG2 and ABCC1 transporters and their potential to overcome multidrug resistance in vitro Daniela CihalovaFrantisek StaudMartina Ceckova Original Article 19 May 2015 Pages: 105 - 116
Development of a new equation to estimate creatinine clearance in cancer patients Michael P. ChuLarissa McCawMichael B. Sawyer Original Article 19 May 2015 Pages: 117 - 124
Comparison of the pharmacokinetics of erlotinib administered in complete fasting and 2 h after a meal in patients with lung cancer Yuki KatsuyaYutaka FujiwaraAkinobu Hamada Original Article 21 May 2015 Pages: 125 - 132
Safety, tolerability, and efficacy of oxaliplatin-based adjuvant chemotherapy after curative resection of hepatic or extrahepatic metastases of Stage IV colorectal cancer Izuma NakayamaMitsukuni SuenagaToshiharu Yamaguchi Original Article 21 May 2015 Pages: 133 - 139
Gemcitabine plus split-dose cisplatin could be a promising alternative to gemcitabine plus carboplatin for cisplatin-unfit patients with advanced urothelial carcinoma Yi Rang KimJae Lyun LeeHanjong Ahn Original Article 23 May 2015 Pages: 141 - 153
Phase II study of erlotinib in elderly patients with non-small cell lung cancer harboring epidermal growth factor receptor mutations Yusuke InoueNaoki InuiTakafumi Suda Original Article 24 May 2015 Pages: 155 - 161
Correlation between BRCA1 and TopBP1 protein expression and clinical outcome of non-small cell lung cancer treated with platinum-based chemotherapy Lin-run WangLin-Juan HeJian Chen Original Article 24 May 2015 Pages: 163 - 170
A single-dose PK study of onapristone including the effect of food on absorption Keyvan RezaiDidier ChassardFrançois Lokiec Original Article 26 May 2015 Pages: 171 - 177
Inhibition of prostate cancer cell growth by 3′,4′,5′-trimethoxyflavonol (TMFol) C. U. F. Kelly HillShaban E. A. SaadLynne M. Howells Original Article 29 May 2015 Pages: 179 - 185
Pharmacodynamic study of axitinib in patients with advanced malignancies assessed with 18F-3′deoxy-3′fluoro-l-thymidine positron emission tomography/computed tomography Justine Yang BrucePeter Colin ScullyGlenn Liu Original Article 29 May 2015 Pages: 187 - 195
A phase II study of biweekly S-1 and paclitaxel (SPA) as first-line chemotherapy in patients with metastatic or advanced gastric cancer Haiping JiangJiong QianNong Xu Clinical Trial Report 27 May 2015 Pages: 197 - 203
Comparison of saliva interleukin-2 concentration to the condition of gums in children with acute lymphoblastic leukaemia during anti-tumour treatment Elżbieta Pels Short Communication Open access 16 May 2015 Pages: 205 - 210
Effect of bendamustine in combination with rituximab on QT interval duration in patients with advanced de novo indolent non-Hodgkin or mantle cell lymphoma John M. BurkeRichard H. C. van der JagtDavid A. MacDonald Short Communication 26 May 2015 Pages: 211 - 216
Erratum to: Docetaxel, cisplatin, and fluorouracil combination in neoadjuvant setting in the treatment of locally advanced gastric adenocarcinoma: Phase II NEOTAX study Nuriye OzdemirHuseyin AbaliNurullah Zengin Erratum 12 June 2015 Pages: 217 - 217
